Humacyte Financials
| HUMAW Stock | USD 0.95 0.06 6.74% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.03 | 5.19 |
|
|
The financial analysis of Humacyte is a critical element in measuring its lifeblood. Investors should not minimize Humacyte's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Humacyte | Select Account or Indicator |
Understanding current and past Humacyte Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Humacyte's financial statements are interrelated, with each one affecting the others. For example, an increase in Humacyte's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Humacyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Humacyte. Check Humacyte's Beneish M Score to see the likelihood of Humacyte's management manipulating its earnings.
Humacyte Stock Summary
Humacyte competes with Humacyte, and Quantum Si. Humacyte is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 44486Q111 020751111 |
| Location | North Carolina; U.S.A |
| Business Address | 2525 East North |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.humacyte.com |
| Phone | 919 313 9633 |
| Currency | USD - US Dollar |
Humacyte Key Financial Ratios
| Return On Equity | -8.51 | ||||
| Gross Profit | (77.4 M) | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Book Value Per Share | (0.53) X |
Humacyte Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 106.7M | 286.5M | 204.3M | 128.2M | 147.5M | 196.8M | |
| Other Current Liab | 4.6M | 6.8M | 7.1M | 9.3M | 10.7M | 7.8M | |
| Net Debt | (11.1M) | (169.0M) | (102.0M) | (22.9M) | (20.6M) | (21.7M) | |
| Retained Earnings | (388.1M) | (414.6M) | (426.5M) | (537.3M) | (483.6M) | (507.8M) | |
| Accounts Payable | 2.3M | 2.1M | 1.6M | 6.5M | 7.5M | 7.8M | |
| Cash | 39.9M | 217.5M | 149.8M | 80.4M | 92.5M | 127.9M | |
| Other Current Assets | 1.4M | 3.7M | 4.6M | 2.8M | 3.3M | 2.9M | |
| Total Liab | 457.0M | 164.4M | 87.4M | 114.7M | 103.2M | 137.6M | |
| Total Current Assets | 41.4M | 229.3M | 154.2M | 83.3M | 95.8M | 132.7M | |
| Common Stock | 1K | 536.7M | 543.5M | 10K | 11.5K | 10.9K |
Humacyte Key Income Statement Accounts
The reason investors look at the income statement is to determine what Humacyte's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 2.2M | 4.3M | 6.2M | 1.1M | 1.3M | 1.2M | |
| Gross Profit | (6.9M) | 1.2M | (6.7M) | (76.6M) | (68.9M) | (65.5M) | |
| Operating Income | (64.6M) | (81.2M) | (84.6M) | (100.0M) | (90.0M) | (94.5M) | |
| Ebit | (64.7M) | (81.2M) | (5.8M) | (104.2M) | (119.8M) | (125.8M) | |
| Research Development | 54.1M | 61.3M | 63.3M | 76.6M | 88.0M | 72.8M | |
| Ebitda | (56.2M) | (73.0M) | 2.5M | (96.5M) | (110.9M) | (116.5M) | |
| Cost Of Revenue | 8.4M | 49K | 8.3M | 76.6M | 88.0M | 92.4M | |
| Income Before Tax | (66.5M) | (26.5M) | (12.0M) | (110.8M) | (127.4M) | (133.8M) | |
| Net Income | (68.7M) | 37.5M | 64.2M | (110.8M) | (127.4M) | (121.0M) |
Humacyte Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Humacyte's current stock value. Our valuation model uses many indicators to compare Humacyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Humacyte competition to find correlations between indicators driving Humacyte's intrinsic value. More Info.Humacyte is rated # 4 in return on equity category among its peers. It also is rated # 4 in return on asset category among its peers . At this time, Humacyte's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Humacyte by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Humacyte Systematic Risk
Humacyte's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Humacyte volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Humacyte correlated with the market. If Beta is less than 0 Humacyte generally moves in the opposite direction as compared to the market. If Humacyte Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Humacyte is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Humacyte is generally in the same direction as the market. If Beta > 1 Humacyte moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Humacyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Humacyte's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Humacyte growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Humacyte March 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Humacyte help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Humacyte. We use our internally-developed statistical techniques to arrive at the intrinsic value of Humacyte based on widely used predictive technical indicators. In general, we focus on analyzing Humacyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Humacyte's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 51.58 | |||
| Value At Risk | (9.45) | |||
| Potential Upside | 12.26 |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.